RT Journal Article
SR Electronic
T1 Sudden Onset of Interstitial Lung Disease Induced by Gefitinib in a Lung Cancer Patient with Multiple Drug Allergy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 415
OP 418
VO 25
IS 1B
A1 KEISUKE AOE
A1 AKIO HIRAKI
A1 TOMOYUKI MURAKAMI
A1 TADASHI MAEDA
A1 YOSHIKI UMEMORI
A1 HIDEKI KATAYAMA
A1 RYOSUKE EDA
A1 HIROYASU TAKEYAMA
YR 2005
UL http://ar.iiarjournals.org/content/25/1B/415.abstract
AB Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor tyrosine kinase which is effective for patients with advanced non-small cell lung cancer. A 75-year-old man with advanced adenocarcinoma of the lung was treated with gefitinib. He had a history of allergy to several antibiotics and Welder's lung. Two days after initiation, he developed acute interstitial lung disease (ILD) and died of respiratory failure due to progression of ILD. Critical assessment pointed to gefitinib as the likely cause of this complication. This is the first report of rapid gefitinib-induced ILD. This case should alert physicians to the potential for dangerous pulmonary side-effects of gefitinib therapy, especially in patients with drug allergy. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved